Over the past decade, there have been important breakthroughs in our understanding of the regulation and function of sex hormone–binding globulin (SHBG). A recent genome-wide association and Mendelian randomization study has provided new insights at the population level. Thorough study of genetic variants affecting serum SHBG has identified de novo lipogenesis as one of the mechanistic links between the metabolic syndrome and reduced serum SHBG levels in humans. Furthermore, careful deduction of the Mendelian randomization results suggests a direct, causal role for SHBG in the pathogenesis of type 2 diabetes, as a hepatokine, in women. These findings prompt the development of SHBG-raising therapies as a means to prevent or treat disorders such as type 2 diabetes and polycystic ovary syndrome.

在过去的十年中，我们对性激素结合球蛋白（SHBG）的调节和功能的理解有了重要的突破。最近的全基因组关联和孟德尔随机化研究在人群水平上提供了新的见解。对影响血清 SHBG 的遗传变异的彻底研究已确定从头脂肪生成是代谢综合征与人类血清 SHBG 水平降低之间的机制联系之一。此外，对孟德尔随机化结果的仔细推论表明，SHBG 作为一种肝因子在女性 2 型糖尿病的发病机制中具有直接的因果作用。这些发现促进了 SHBG 升高疗法的发展，以作为预防或治疗 2 型糖尿病和多囊卵巢综合征等疾病的一种手段。